Achillion Pharmaceuticals
ACHN
ACHN was delisted on the 27th of January, 2020.
93 hedge funds and large institutions have $263M invested in Achillion Pharmaceuticals in 2013 Q4 according to their latest regulatory filings, with 18 funds opening new positions, 28 increasing their positions, 37 reducing their positions, and 26 closing their positions.
568% more call options, than puts
Call options by funds: $42.6M | Put options by funds: $6.38M
7% more capital invested
Capital invested by funds: $245M → $263M (+$17.6M)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
9% less funds holding
Funds holding: 102 → 93 (-9)
24% less repeat investments, than reductions
Existing positions increased: 28 | Existing positions reduced: 37
31% less first-time investments, than exits
New positions opened: 18 | Existing positions closed: 26
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$25.9M |
| 2 |
State Street
Boston,
Massachusetts
|
+$5.71M |
| 3 |
BC
Broadfin Capital
New York
|
+$2.9M |
| 4 |
VAM
Visium Asset Management
New York
|
+$2.68M |
| 5 |
DAM
Doheny Asset Management
Los Angeles,
California
|
+$2.64M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$16.7M |
| 2 |
JHIU
Janus Henderson Investors US
Denver,
Colorado
|
-$7.28M |
| 3 |
UBS AM
Chicago,
Illinois
|
-$5.98M |
| 4 |
Wells Fargo
San Francisco,
California
|
-$4.45M |
| 5 |
WSA
Wall Street Associates
Lajolla,
California
|
-$3.48M |
ACHN Hedge Fund Activity: Q4 2013 in Review
93 of the 3,447 institutional investors tracked by Wall St. Rank reported a position in Achillion Pharmaceuticals (ACHN) for Q4 2013, worth a combined $263M — up 7.2% from $245M a quarter earlier.
Sellers outnumbered buyers: 26 funds closed out of ACHN and 18 opened new positions — a net loss of 8 holders — while 37 trimmed existing stakes and 28 added.
The largest buyer was RA Capital Management, adding an estimated $25.9M. The largest seller was Fidelity Investments, cutting an estimated $16.7M.
- 93 institutional investors held Achillion Pharmaceuticals (ACHN) as of Q4 2013, down from 102 in Q3 2013.
- Funds reported $263M of Achillion Pharmaceuticals stock for Q4 2013, up 7.2% quarter-over-quarter.
- 18 funds opened new Achillion Pharmaceuticals positions in Q4 2013 and 26 closed out, a net change of -8 holders.
- The largest Achillion Pharmaceuticals buyer in Q4 2013 was RA Capital Management, an estimated $25.9M added.
- The largest Achillion Pharmaceuticals seller in Q4 2013 was Fidelity Investments, an estimated $16.7M sold.
Based on aggregated 13F filings for Q4 2013.